XNAS
HSIC
Market cap9.53bUSD
Oct 08, Last price
84.63USD
1D
1.16%
1Q
0.27%
Jan 2017
42.25%
Name
Henry Schein Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.
Related entities
Subsidiaries (29)
HENRY SCHEIN S.R.O.
HENRY SCHEIN SERVICES GMBH
Jorgen Kruuse A/S
MARRODENT SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Medivet Spolka Akcyjna
NINGBO BAIYIXING MEDICAL EQUIPMENT CO., LTD.
OPTIDENT LIMITED
SHANGHAI HANRUIXIANG TRADING CO., LTD. EXISTENCE (IN OPERATION, OPENED, REGISTERED)
VICTORY ALPHA LIMITED
Key people
Andrea Albertini
Chief Executive Officer - Global Distribution and Technology · since 2025
R. Boggan
Co-Chief Executive Officer - Global Oral Reconstruction Group · since 2024
Thomas Popeck
Chief Executive Officer - Henry Schein Products Group · since 2025
Bridget Ross
President of Global Medical Group · since 2017
Bianka Wilson
Co-Chief Executive Officer - Global Oral Reconstruction Group · since 2024
Michael Ettinger
Chief Operating Officer, Executive Vice President · since 2022
Christine Sheehy
Chief Human Resources Officer, Senior Vice President · since 2024
Mark Mlotek
Executive Vice President, Chief Strategic Officer · since 2025
David Kochman
Senior Vice President, Chief Corporate Affairs Officer · since 2025
James Mullins
Senior Vice President - Global Supply Chain · since 2018
Christopher Pendergast
Senior Vice President, Chief Technology Officer · since 2019
Walter Siegel
Senior Vice President, Chief Legal Officer · since 2021
Ronald South
Chief Financial Officer, Senior Vice President · since 2022
Kelly Murphy
Senior Vice President, General Counsel · since 2021
Lead Independent Director · since 2012
Chief Executive Officer, Director · since 2026
Independent Director · since 2021
William Daniel
Independent Director · since 2025
Independent Director · since 2021
Independent Director · since 2023
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
135 DURYEA RD
MELVILLE, NY 11747
US
MELVILLE, NY 11747
US
Previous name
HENRY SCHEIN USA, INC.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2021‑12 | 2020‑12 | 2020‑12 | 2019‑12 | 2019‑12 | 2018‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||||
Revenues | |||||||||||||||
Cost of revenue | |||||||||||||||
Unusual Expense (Income) | |||||||||||||||
NOPBT | |||||||||||||||
NOPBT Margin | |||||||||||||||
Operating Taxes | |||||||||||||||
Tax Rate | |||||||||||||||
NOPAT | |||||||||||||||
Net income | |||||||||||||||
Dividends | |||||||||||||||
Dividend yield | |||||||||||||||
Proceeds from repurchase of equity | |||||||||||||||
BB yield | |||||||||||||||
| Debt | |||||||||||||||
Debt current | |||||||||||||||
Long-term debt | |||||||||||||||
Deferred revenue | |||||||||||||||
Other long-term liabilities | |||||||||||||||
Net debt | |||||||||||||||
| Cash flow | |||||||||||||||
Cash from operating activities | |||||||||||||||
CAPEX | |||||||||||||||
Cash from investing activities | |||||||||||||||
Cash from financing activities | |||||||||||||||
FCF | |||||||||||||||
| Balance | |||||||||||||||
Cash | |||||||||||||||
Long term investments | |||||||||||||||
Excess cash | |||||||||||||||
Stockholders' equity | |||||||||||||||
Invested Capital | |||||||||||||||
ROIC | |||||||||||||||
ROCE | |||||||||||||||
| EV | |||||||||||||||
Common stock shares outstanding | |||||||||||||||
Price | |||||||||||||||
Market cap | |||||||||||||||
EV | |||||||||||||||
EBITDA | |||||||||||||||
EV/EBITDA | |||||||||||||||
Interest | |||||||||||||||
Interest/NOPBT | |||||||||||||||